Last reviewed · How we verify
Human Coagulation FACTOR X
Human Coagulation FACTOR X, marketed by Bio Products Laboratory, is an established product in the coagulation therapy segment. A key strength of the product is its patent protection, which extends to 2028, providing a significant barrier to generic competition. The primary risk is the lack of detailed revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Human Coagulation FACTOR X |
|---|---|
| Sponsor | Bio Products Laboratory |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis (PHASE3)
- Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery (PHASE4)
- Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin (PHASE1)
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- Coagulation in Cirrhosis (PHASE4)
- A Gene Transfer Study for Hemophilia A (PHASE1, PHASE2)
- Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant (PHASE1)
- Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Coagulation FACTOR X CI brief — competitive landscape report
- Human Coagulation FACTOR X updates RSS · CI watch RSS
- Bio Products Laboratory portfolio CI